Compare Page
Retatrutide vs Tirzepatide
Quick verdict: Retatrutide vs Tirzepatide is the next-generation incretin comparison. Retatrutide is a first-in-class triple GLP-1/GIP/glucagon receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. The critical differentiator is retatrutide’s glucagon receptor component, which adds direct energy-expenditure and hepatic fat-oxidation pathways beyond appetite suppression. Phase 2 data showed retatrutide producing up to 24.2% mean weight loss at 48 weeks — the largest ever reported for any anti-obesity medication — and an extraordinary 82.4% liver fat reduction in MASLD patients.[1][2][3] Tirzepatide, already FDA-approved, has demonstrated up to 22.5% weight loss and has an established safety profile across multiple Phase 3 programmes.[4] The trade-off: retatrutide may be more potent, but tirzepatide has dramatically more safety data and regulatory approval.
Read the full peptide profiles: Retatrutide and Tirzepatide.
At a Glance: Retatrutide vs Tirzepatide
How They Work
Tirzepatide and retatrutide share a common lineage — both developed by Eli Lilly — but represent different generations of incretin engineering. Tirzepatide activates two receptors: GIP and GLP-1. The GLP-1 component suppresses appetite through central hypothalamic signalling and slows gastric emptying, while the GIP component potentiates insulin sensitivity and may provide additive metabolic effects. This dual mechanism earned tirzepatide the “twincretin” label and produced weight loss results that exceeded all prior single-agonist compounds.[4][5]
Retatrutide adds a third receptor: glucagon. This is the critical pharmacological innovation. While GLP-1 and GIP primarily reduce energy intake (appetite suppression, insulin regulation), glucagon receptor activation directly increases energy expenditure through hepatic fat oxidation, thermogenesis, and amino acid catabolism. Coskun et al. (2022) described this as a “push-pull” mechanism — GLP-1/GIP reduces input while glucagon increases output — and demonstrated superior weight loss versus dual agonism in preclinical models.[6] This mechanistic advantage is likely why retatrutide produced unprecedented weight loss and dramatic liver fat clearance in Phase 2 trials.[1][3]
Both compounds use fatty acid modifications for albumin binding and extended half-lives (5-6 days), enabling once-weekly administration. The fundamental difference is not engineering but pharmacology: two receptor targets versus three, appetite suppression alone versus appetite suppression plus metabolic acceleration. For comparison with single-pathway GLP-1 agonists, see Tirzepatide vs Semaglutide.
Evidence Comparison
Tirzepatide’s evidence base is substantial and mature. The SURPASS programme (T2D) includes multiple Phase 3 trials, including SURPASS-2 which directly compared tirzepatide to semaglutide. The SURMOUNT programme (obesity) demonstrated up to 22.5% mean weight loss at 72 weeks, with long-term extension data (SURMOUNT-4) showing weight maintenance during continued treatment and regain upon discontinuation. The compound has regulatory approvals for both T2D (Mounjaro) and obesity (Zepbound), with post-marketing surveillance data accumulating across millions of prescriptions.[4][5]
Retatrutide’s evidence is earlier-stage but extraordinary in magnitude. The Phase 2 obesity trial published in NEJM showed up to 24.2% mean weight loss at 48 weeks — with 100% of participants on the highest dose losing ≥5% body weight and 63% losing ≥20%. Critically, the weight-loss trajectory was still descending at 48 weeks, suggesting even greater reductions with longer treatment.[1] The Phase 2 T2D trial (Lancet) showed HbA1c reductions of up to 2.0% alongside 16.9% weight loss.[2] Perhaps most impressive, the MASLD sub-study (Nature Medicine) demonstrated 82.4% liver fat reduction — the largest hepatic fat clearance ever reported for any incretin-class compound.[3]
The fundamental trade-off is clear: retatrutide produces more impressive efficacy signals but from Phase 2 data only. Tirzepatide has Phase 3 validation, regulatory approval, and real-world safety data. Phase 2 results do not always replicate exactly in Phase 3. The TRIUMPH Phase 3 programme is currently enrolling across obesity, T2D, OSA, and osteoarthritis indications and will provide the definitive data.[7]
When Each Fits Better
Retatrutide may be of greater research interest when:
- Maximum weight-loss magnitude is the primary endpoint — Phase 2 data shows the largest reductions ever recorded for any pharmacological intervention[1]
- Liver fat / MASLD resolution is a key outcome — 82.4% hepatic fat reduction is unmatched by any other compound in this class[3]
- The energy-expenditure component (glucagon receptor) is mechanistically relevant to the research question[6]
- Triple receptor pharmacology and novel agonist mechanisms are the subject of investigation
Tirzepatide is the stronger option when:
- Regulatory approval and established safety data are required — tirzepatide is FDA-approved with extensive Phase 3 and post-marketing data[4]
- Glycaemic control in type 2 diabetes is the primary context — SURPASS programme provides robust T2D evidence[5]
- Long-term data is needed — SURMOUNT extension data provides 88+ weeks of safety information
- Clinical application rather than investigational research is the context — tirzepatide is commercially available
Head-to-Head
No direct head-to-head trial between retatrutide and tirzepatide has been published. The comparison currently rests on cross-trial inference, which has significant limitations: different populations, durations, dose-escalation schedules, and endpoint definitions. That said, the directional signals are noteworthy: retatrutide achieved ~24.2% weight loss at 48 weeks (still declining) versus tirzepatide’s ~22.5% at 72 weeks (approaching plateau). If retatrutide’s trajectory continued to 72 weeks, the gap could widen further.[1][4]
The liver fat data presents the starkest contrast. Retatrutide’s 82.4% hepatic fat reduction in the MASLD sub-study is dramatically greater than any liver-related data from tirzepatide trials. This is likely attributable to the glucagon receptor component, which directly promotes hepatic fat oxidation — a mechanism tirzepatide lacks. For MASLD/NAFLD research contexts, this distinction may be the most clinically meaningful difference between the two compounds.[3][6]
On tolerability, both share GI-predominant side-effect profiles (nausea, diarrhoea, vomiting). Retatrutide’s glucagon component theoretically adds hepatic glucose output, but Phase 2 T2D data showed net glycaemic improvement, indicating the GLP-1/GIP components compensate effectively.[2] The critical unknown is long-term safety: sustained glucagon receptor agonism at this level is genuinely novel, and multi-year data will only come from the TRIUMPH Phase 3 programme.[7]
FAQ
Is retatrutide more effective than tirzepatide for weight loss?
Phase 2 data suggests retatrutide produces greater weight loss — up to 24.2% at 48 weeks versus tirzepatide’s 22.5% at 72 weeks — with the weight-loss trajectory still declining at study end.[1][4] However, these are cross-trial comparisons from different populations and timepoints. A definitive head-to-head trial has not been conducted. Phase 3 data (TRIUMPH) will provide more conclusive evidence.
Why does retatrutide have a glucagon component?
Glucagon receptor activation adds a fundamentally different metabolic pathway. While GLP-1 and GIP primarily reduce caloric intake (appetite suppression), glucagon increases caloric output through hepatic fat oxidation, thermogenesis, and energy expenditure. This “push-pull” approach — reducing input while increasing output — provides a dual mechanism for weight loss that appetite suppression alone cannot achieve. It also explains the extraordinary liver fat reductions seen in the MASLD trial.[3][6]
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH programme) across multiple indications. If Phase 3 results are positive and regulatory submissions proceed on schedule, FDA approval could potentially occur in the 2027-2028 timeframe. However, clinical development timelines are inherently uncertain, and any safety signals in Phase 3 could alter the trajectory.[7]
Should I switch from tirzepatide to retatrutide?
This is a clinical decision that should be made with a qualified healthcare provider. Tirzepatide is FDA-approved with extensive safety data. Retatrutide is investigational and not yet available outside clinical trials. Until Phase 3 data is complete and regulatory approval is obtained, tirzepatide remains the established option with proven efficacy and safety.[4]
References
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, Phase 2 trial. Lancet. 2023;402(10401):529-544. PMID: 38858523.
- Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine. 2024. PMID: 41090431.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
- Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647.
- Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycaemic control and weight loss. Cell Metabolism. 2022;34(8):1234-1247. PMID: 35985340.
- Giblin MJ, et al. Rationale and design of the TRIUMPH registration programme for retatrutide. Diabetes Obes Metab. 2026. (Phase 3 design paper).